La vacuna contra la COVID-19 de HIPRA genera en adolescentes una respuesta inmunitaria amplia y duradera frente al SARS-CoV-2, como la demostrada en adultos 23 October 2026
La vacuna contra la COVID-19 d’HIPRA genera en adolescents una resposta immunitària àmplia i duradora contra el SARS-CoV-2, com la demostrada en adults 23 October 2026
HIPRA’s COVID-19 vaccine generates a broad and long-lasting immune response to SARS-CoV-2 in adolescents, as demonstrated in adults 23 October 2026
“For once, we were the priority”: What a vaccine trial taught us about trust, reciprocity, and inclusion 11 August 2025
Marking the Close of RBDCOV: Final Event in Barcelona Highlights Legacy and Lessons Learned 30 July 2025
